Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
At 72, Kathie Lee Gifford says aging isn’t what she expected. 'The golden years? It’s a lie.’ - 2Jupiter and the moon take a sunset stroll on March 26. Here's how to see it
- 3Vote in favor of Your #1 Home Exercise Gear: Execution and Comfort Matter
- 4Kansas school officials report high student illness, dismiss early
- 5Lily Allen 2026 'West End Girl' Tour: How to get tickets, prices, presale info and more
- 'Wicked: For Good' was filmed at this surreal National Park in Egypt
- WHO issues guidance on GLP-1 drugs for obesity
- Regeneron's experimental therapy combo effective in untreated cancer patients
- Artemis 2 moon rocket gets 'America 250' paint job | Space photo of the day for Dec. 23, 2025
- Fundamental Home Items Each Animal person Needs
- Philippines evacuates 3,000 villagers after volcano activity raises alert level
- Where You Could Sleep With Snorlax in Japan, From MIMARU’s Pokémon Rooms to Grand Hyatt Tokyo’s Limited Pokémon Suite
- Big Bear glows with big stars | Space photo of the day for Dec. 31, 2025
- The Most recent Microsoft Surface Genius PC: Ideal for Very good quality Planning and Gaming Needs
